Kiri

Estimating the burden of tuberculosis infection in the EU/EEA 1/3 European Centre for Disease Prevention and Control (ECDC) Gustav den III:s Boulevard 40, 169 73 Solna, Sweden Phone: +46 (0)8 58 60 10 00 - Fax: +46 (0)8 58 60 10 01

www.ecdc.europa.eu

ECDC NORMAL

ECDC Project synopsis

Estimating the burden of tuberculosis infection in the EU/EEA

(2024-2027)

Background • TB infection (TBI) prevalence has been estimated for Europe, at 11- 15%1,2.

• Country-specific TBI estimates are not available for Member States of the European Union/European Economic Area.

• Available TBI estimates for specific at-risk populations are ‘fragmented’.

Relevance Country-level evidence would better support the development of policy to ensure availability of TB preventative treatment (TPT) to manage TB infection and progression to TB disease.

Project Purpose The scope of this project is to estimate the prevalence of tuberculosis (TB) infection and rate of progression to active TB in at-risk groups among selected countries in the EU/EEA.

Project Objectives 1. To assess the feasibility of generating these estimates in each country of the EU/EEA;

2. To estimate TBI prevalence and rate of progression to active TB in at-risk groups for 6 -9 EU/EEA countries selected based on feasibility;

3. To present TBI prevalence and rate of progression to active to TB in at-risk groups at the national level; 4. To identify key challenges around TBI management and action points for ECDC consideration.

At-risk populations of interest • Household and close contacts • Immigrants and asylum seekers • People with underlying medical conditions • Homeless populations • Additional country-specific risk populations

1 Houben RMGJ, Dodd PJ (2016) The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med 13(10): e1002152. https://doi.org/10.1371/journal.pmed.1002152 2 Guthmann JP, Haas W. Tuberculosis in the European Union/European Economic Area: much progress, still many challenges. Euro Surveill. 2019 Mar;24(12):1900174. doi: 10.2807/1560-7917.ES.2019.24.12.1900174. PMID: 30914075; PMCID: PMC6440586.

(2024-2027) 2/3 European Centre for Disease Prevention and Control (ECDC) Gustav den III:s Boulevard 40, 169 73 Solna, Sweden Phone: +46 (0)8 58 60 10 00 - Fax: +46 (0)8 58 60 10 01

www.ecdc.europa.eu

ECDC NORMAL

Methodological Approach

Project Outputs

Country Benefits Participating countries will benefit by having estimates on TBI prevalence and rate of progression to TB disease, and knowledge and experience to update these estimates when there are changes in at-risk populations, or risk factors.

Selection of maximum 9 EU/EEA countries based on feasibility assessment If >9 countries are eligible for phase 2, geography, population size, and TB burden will be

taken into account for the final selection.

Phase 1: Feasibility assessment • Overall report • Country-specific reports • Manuscript TBD

Phase 2: TBI prevalence estimates • Overall report • Country-specific reports • Manuscript

(2024-2027) 3/3 European Centre for Disease Prevention and Control (ECDC) Gustav den III:s Boulevard 40, 169 73 Solna, Sweden Phone: +46 (0)8 58 60 10 00 - Fax: +46 (0)8 58 60 10 01

www.ecdc.europa.eu

ECDC NORMAL

Project Consortium

Prof. Dr. Pete Dodd (TB modeller)

Saatja: Tuberculosis <[email protected]>

Saadetud: 19.08.2024 14:09

Adressaat: Költringer Fiona <[email protected]>; Indra Alexander

<[email protected]>; Vinciane SIZAIRE <[email protected]>;

Wouter Arrazola de Oñate <[email protected]>; Yuliana

Atanasova <[email protected]>; zvjezdana.lovric

<[email protected]>; goranka.petrovic <[email protected]>;

coconstantinou <[email protected]>; Anna Papandreou

<[email protected]>; vera.dvorakova <[email protected]>; Jiří

Wallenfels <[email protected]>; Anders Koch <[email protected]>; Troels

Lillebæk <[email protected]>; <[email protected]>; Piret Viiklepp

<[email protected]>; Silja Mentula <[email protected]>; Silja

Mentula <[email protected]>; Hanna Soini <[email protected]>;

Delphine Viriot <[email protected]>; Jean-Paul

GUTHMANN <[email protected]>; KroegerS

<[email protected]>; haasw <[email protected]>; s.chatzianastasiou

<[email protected]>; bakosagi <[email protected]>; Kamilla

Sigríður Jósefsdóttir - Landl <[email protected]>; Phil Downes

<[email protected]>; Mary O' Meara <[email protected]>; Cirillo

Daniela <[email protected]>; Sane Schepisi Monica

<[email protected]>; Šarlote Konova <[email protected]>;

Ieva Rimšāne <[email protected]>; Walser-Domjan Esther

<[email protected]>; Alvyda Naujokaitė

<[email protected]>; Jurgita Pakalniškienė

<[email protected]>; Anne Vergison <[email protected]>;

Irène Demuth <[email protected]>; Melillo Tanya at Health

Regulation <[email protected]>; Geraldine Ter Linde

<[email protected]>; Richard Anthony <[email protected]>;

Karine Nordstrand <[email protected]>; Anne.Torunn.Mengshoel

<[email protected]>; s.wesolowski

<[email protected]>; Maria Korzeniewska-Koseła

<[email protected]>; afssmd <[email protected]>;

<[email protected]>; Nicoleta Cioran

<[email protected]>; <[email protected]>; Ivan Solovič

<[email protected]>; Sanja Grm Zupan <[email protected]>;

petra.svetina <[email protected]>; zherrador

<[email protected]>; Carlos Peralta <[email protected]>;

petra.edquist <[email protected]>; maria.axelsson

<[email protected]>

Koopia: NC_CCB_Austria <[email protected]>; sigrid.kiermayr

<[email protected]>; koen.blot

<[email protected]>; <[email protected]>; Zhivka Getsova

<[email protected]>; Iva Christova <[email protected]>; kcapak

<[email protected]>; bernard.kaic <[email protected]>; Elisavet

Constantinou <[email protected]>; <[email protected]>; Hana

Orlíková <[email protected]>; Kamilla Grønborg Laut <[email protected]>;

Stine Ulendorf Jacobsen <[email protected]>; Kärt Sõber

<[email protected]>; TA Info <[email protected]>; Hanna Sepp

<[email protected]>; Otto Helve <[email protected]>; Savolainen-

Kopra Carita <[email protected]>; Paula GARCIA-LOBATO

<[email protected]>; Anne-Catherine VISO <anne-

[email protected]>; Lea Rathmachers

<[email protected]>; <[email protected]>; Rexroth, Ute <[email protected]>;

AnderHeidenMa <[email protected]>; Theodora Kalomama

<[email protected]>; Dimitrios Paraskevis

<[email protected]>; Christakis Chatzichristodoulou

<[email protected]>; <[email protected]>;

phc.office <[email protected]>; Rezsőfi Judit

<[email protected]>; Guðrún Aspelund - Landl

<[email protected]>; lois.oconnor <[email protected]>;

Kate Loughnane <[email protected]>; patricia.garvey

<[email protected]>; Louise Cullen <[email protected]>;

Lisa.Domegan <[email protected]>; Aine Grace <[email protected]>;

Francesco Maraglino <[email protected]>; Antra Bormane

<[email protected]>; Dehler Silvia, Dr. med.

<[email protected]>; Jurgita Pakalniškienė

<[email protected]>; greta.gargasiene

<[email protected]>; Jurgita Pakalniškienė

<[email protected]>; Jean-Claude Schmit <jean-

[email protected]>; Gauci Charmaine at Health Regulation

<[email protected]>; Hester.de.Melker <[email protected]>;

Susan van den Hof <[email protected]>; Macdonald, Emily Ann

<[email protected]>; Heidi Lange <[email protected]>; Zacharczuk

Katarzyna <[email protected]>; Mariana Ferreira

<[email protected]>; Pedro Licinio Pinto Leite

<[email protected]>; <[email protected]>; André Peralta

Santos <[email protected]>; Adriana Pistol

<[email protected]>; ecdc <[email protected]>; jan.mikas

<[email protected]>; <[email protected]>; Marta.vitek

<[email protected]>; Simón Soria. Fernando <[email protected]>;

<[email protected]>;

<[email protected]>; Agneta Falk Filipsson

<[email protected]>; Sara Bengtsson

<[email protected]>; birgitta.lesko

<[email protected]>; anette.richardson

<[email protected]>; Jozefien Groenendijk

<[email protected]>; Mergenthaler, Christina

<[email protected]>; Ineke Spruijt <[email protected]>; Senia

Rosales-Klintz <[email protected]>; Tuberculosis

<[email protected]>

Teema: For information: Feasibility assessment for the project

‘Estimating the burden of tuberculosis infection in the EU/EEA’

Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu

saatja korral palume linke ja faile mitte avada.

ECDC NORMAL

To: National Focal Points for Tuberculosis

CC: National Coordinators, ECDC contractors, ECDC project manager

Dear National Focal Point for Tuberculosis,

The European Centre for Disease Prevention and Control (ECDC) has

contracted a consortium of experts from KIT Royal Tropical Institute

(lead partner), KNCV Tuberculosis Foundation, Sheffield Centre for Health

and Related Research and the Amsterdam Institute for Global Health and

Development to implement the project Estimating the burden of

tuberculosis infection in the EU/EEA.

The objective of the project is to estimate the prevalence of

tuberculosis (TB) infection and rate of progression to TB disease in at-

risk groups among selected countries in the EU/EEA.

This project was introduced to the ECDC TB Disease Network during the

meeting held in mid-May in the Netherlands. Enclosed please find a

synopsis of the project for your information.

The first phase of the project consists of a feasibility study to assess

the availability and accessibility of already existing data sources

necessary for generating country-specific estimates of TB infection

prevalence and progression to TB disease in pre-defined at-risk

populations.

We would appreciate your contribution to this feasibility study by

completing an online survey.

In the upcoming days you will receive an email invite from Ineke Spruijt

([email protected]) to complete the survey. Please note we are

kindly requesting only one reply per country. Further information and

guidance will be shared in the invitation email.

Should you have any questions about the project, please feel free to

contact me ( ) and Ineke Spruijt ().

Best regards,

Senia Rosales-Klintz (project manager)

European Centre for Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone &#43;46 (0)8 58 60 10 00

Follow ECDC on:

Confidentiality NoticeIf you are not the intended recipient of this

message, you are hereby kindly requested, to, consecutively, refrain from

disclosing its content to any third party, delete it and inform its

sender of the erroneous transmittal.